Which has better valuation & earnings, CRSP or HROW?

Harrow has higher revenue and earnings than CRISPR Therapeutics. Harrow is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CRISPR Therapeutics $3.51M 1,489.07 -$581.60M -$6.22 N/A Harrow $272.30M 4.67 -$5.14M -$0.41 N/A

Does the media prefer CRSP or HROW?

In the previous week, CRISPR Therapeutics had 2 more articles in the media than Harrow. MarketBeat recorded 8 mentions for CRISPR Therapeutics and 6 mentions for Harrow. CRISPR Therapeutics' average media sentiment score of 1.29 beat Harrow's score of 1.21 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harrow 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DNTH or HROW?

In the previous week, Harrow had 3 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 6 mentions for Harrow and 3 mentions for Dianthus Therapeutics. Harrow's average media sentiment score of 1.21 beat Dianthus Therapeutics' score of 1.01 indicating that Harrow is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harrow 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend NNNN or HROW?

Harrow has a consensus target price of $69.43, suggesting a potential upside of 103.54%. Given Harrow's stronger consensus rating and higher probable upside, analysts plainly believe Harrow is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Harrow 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64

Which has better valuation and earnings, NNNN or HROW?

Anbio Biotechnology has higher earnings, but lower revenue than Harrow. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 501.87 $6.40M N/A N/A Harrow $272.30M 4.67 -$5.14M -$0.41 N/A

Does the media favor NNNN or HROW?

In the previous week, Harrow had 3 more articles in the media than Anbio Biotechnology. MarketBeat recorded 6 mentions for Harrow and 3 mentions for Anbio Biotechnology. Harrow's average media sentiment score of 1.21 beat Anbio Biotechnology's score of 0.67 indicating that Harrow is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anbio Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harrow 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, INDV or HROW?

Indivior has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indivior $1.24B 3.43 $210M $1.95 17.89 Harrow $272.30M 4.67 -$5.14M -$0.41 N/A

Is INDV or HROW more profitable?

Indivior has a net margin of 19.44% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets Indivior 19.44% -219.26% 29.40% Harrow -5.57% 19.59% 2.26%

Does the media refer more to INDV or HROW?

In the previous week, Harrow had 4 more articles in the media than Indivior. MarketBeat recorded 6 mentions for Harrow and 2 mentions for Indivior. Harrow's average media sentiment score of 1.21 beat Indivior's score of 0.82 indicating that Harrow is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harrow 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, MANE or HROW?

MANE has higher earnings, but lower revenue than Harrow. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MANE N/A N/A N/A N/A N/A Harrow $272.30M 4.67 -$5.14M -$0.41 N/A

Is MANE or HROW more profitable?

MANE has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat MANE's return on equity. Company Net Margins Return on Equity Return on Assets MANE N/A N/A N/A Harrow -5.57% 19.59% 2.26%

Does the media favor MANE or HROW?

In the previous week, MANE and MANE both had 6 articles in the media. Harrow's average media sentiment score of 1.21 beat MANE's score of 0.40 indicating that Harrow is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MANE 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harrow 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Harrow (HROW) Competitors

$34.11 -1.10 (-3.12%)

Closing price 04:00 PM Eastern

Extended Trading

$34.61 +0.50 (+1.47%)

As of 05:03 PM Eastern

Compare

HROW vs. CRSP, DNTH, NNNN, INDV, and MANE

Should you buy Harrow stock or one of its competitors? MarketBeat compares Harrow with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Harrow include CRISPR Therapeutics (CRSP), Dianthus Therapeutics (DNTH), Anbio Biotechnology (NNNN), Indivior (INDV), and MANE (MANE). These companies are all part of the "pharmaceutical products" industry.

How does Harrow compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Harrow (NASDAQ:HROW) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

CRISPR Therapeutics currently has a consensus target price of $65.47, suggesting a potential upside of 20.82%. Harrow has a consensus target price of $69.43, suggesting a potential upside of 103.54%. Given Harrow's stronger consensus rating and higher possible upside, analysts plainly believe Harrow is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.53
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 4.1% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 12.8% of Harrow shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Harrow has higher revenue and earnings than CRISPR Therapeutics. Harrow is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,489.07	-$581.60M	-$6.22	N/A
Harrow	$272.30M	4.67	-$5.14M	-$0.41	N/A

Harrow has a net margin of -5.57% compared to CRISPR Therapeutics' net margin of -13,856.54%. Harrow's return on equity of 19.59% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Harrow	-5.57%	19.59%	2.26%

In the previous week, CRISPR Therapeutics had 2 more articles in the media than Harrow. MarketBeat recorded 8 mentions for CRISPR Therapeutics and 6 mentions for Harrow. CRISPR Therapeutics' average media sentiment score of 1.29 beat Harrow's score of 1.21 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harrow	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CRISPR Therapeutics has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market. Comparatively, Harrow has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

Summary

Harrow beats CRISPR Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Harrow compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Harrow (NASDAQ:HROW) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Harrow has higher revenue and earnings than Dianthus Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,397.17	-$162.34M	-$4.13	N/A
Harrow	$272.30M	4.67	-$5.14M	-$0.41	N/A

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 12.8% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Harrow has a net margin of -5.57% compared to Dianthus Therapeutics' net margin of -12,998.50%. Harrow's return on equity of 19.59% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Harrow	-5.57%	19.59%	2.26%

Dianthus Therapeutics currently has a consensus target price of $117.82, indicating a potential upside of 31.71%. Harrow has a consensus target price of $69.43, indicating a potential upside of 103.54%. Given Harrow's higher probable upside, analysts clearly believe Harrow is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Harrow had 3 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 6 mentions for Harrow and 3 mentions for Dianthus Therapeutics. Harrow's average media sentiment score of 1.21 beat Dianthus Therapeutics' score of 1.01 indicating that Harrow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harrow	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dianthus Therapeutics has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market. Comparatively, Harrow has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market.

Summary

Harrow beats Dianthus Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Harrow compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Harrow (NASDAQ:HROW) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Harrow has a consensus target price of $69.43, suggesting a potential upside of 103.54%. Given Harrow's stronger consensus rating and higher probable upside, analysts plainly believe Harrow is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Anbio Biotechnology has a beta of 4.4, suggesting that its stock price is 340% more volatile than the broader market. Comparatively, Harrow has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

Anbio Biotechnology has higher earnings, but lower revenue than Harrow.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	501.87	$6.40M	N/A	N/A
Harrow	$272.30M	4.67	-$5.14M	-$0.41	N/A

72.8% of Harrow shares are owned by institutional investors. 12.8% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Harrow had 3 more articles in the media than Anbio Biotechnology. MarketBeat recorded 6 mentions for Harrow and 3 mentions for Anbio Biotechnology. Harrow's average media sentiment score of 1.21 beat Anbio Biotechnology's score of 0.67 indicating that Harrow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anbio Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harrow	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anbio Biotechnology has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Anbio Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Harrow	-5.57%	19.59%	2.26%

Summary

Harrow beats Anbio Biotechnology on 10 of the 14 factors compared between the two stocks.

How does Harrow compare to Indivior?

Indivior (NASDAQ:INDV) and Harrow (NASDAQ:HROW) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Indivior presently has a consensus price target of $39.33, indicating a potential upside of 12.77%. Harrow has a consensus price target of $69.43, indicating a potential upside of 103.54%. Given Harrow's higher probable upside, analysts clearly believe Harrow is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Indivior has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.43	$210M	$1.95	17.89
Harrow	$272.30M	4.67	-$5.14M	-$0.41	N/A

Indivior has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Harrow has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

In the previous week, Harrow had 4 more articles in the media than Indivior. MarketBeat recorded 6 mentions for Harrow and 2 mentions for Indivior. Harrow's average media sentiment score of 1.21 beat Indivior's score of 0.82 indicating that Harrow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harrow	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Indivior has a net margin of 19.44% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Harrow	-5.57%	19.59%	2.26%

60.3% of Indivior shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 0.7% of Indivior shares are owned by insiders. Comparatively, 12.8% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Indivior beats Harrow on 9 of the 17 factors compared between the two stocks.

How does Harrow compare to MANE?

MANE (NYSE:MANE) and Harrow (NASDAQ:HROW) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

72.8% of Harrow shares are held by institutional investors. 12.8% of Harrow shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

MANE has higher earnings, but lower revenue than Harrow.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MANE	N/A	N/A	N/A	N/A	N/A
Harrow	$272.30M	4.67	-$5.14M	-$0.41	N/A

In the previous week, MANE and MANE both had 6 articles in the media. Harrow's average media sentiment score of 1.21 beat MANE's score of 0.40 indicating that Harrow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MANE	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harrow	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MANE presently has a consensus target price of $100.00, indicating a potential downside of 1.92%. Harrow has a consensus target price of $69.43, indicating a potential upside of 103.54%. Given Harrow's stronger consensus rating and higher probable upside, analysts clearly believe Harrow is more favorable than MANE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MANE	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

MANE has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat MANE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MANE	N/A	N/A	N/A
Harrow	-5.57%	19.59%	2.26%

Summary

Harrow beats MANE on 9 of the 10 factors compared between the two stocks.

Get Harrow News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HROW vs. The Competition

Export

Metric	Harrow	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.27B	$2.96B	$6.31B	$12.61B
Dividend Yield	N/A	1.83%	2.68%	5.22%
P/E Ratio	-83.19	18.16	21.13	26.68
Price / Sales	4.67	339.00	546.66	114.79
Price / Cash	40.74	55.97	27.44	37.60
Price / Book	24.19	4.02	9.95	6.88
Net Income	-$5.14M	$75.85M	$3.56B	$336.73M
7 Day Performance	3.36%	2.06%	2.12%	4.20%
1 Month Performance	N/A	N/A	N/A	-0.08%
1 Year Performance	20.79%	30.32%	36.38%	40.29%

Harrow Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HROW Harrow	4.6092 of 5 stars	$34.11 -3.1%	$69.43 +103.5%	+24.7%	$1.27B	$272.30M	N/A	180
CRSP CRISPR Therapeutics	2.4709 of 5 stars	$50.36 flat	$65.47 +30.0%	+55.6%	$4.86B	$3.51M	N/A	460	Positive News
DNTH Dianthus Therapeutics	2.6707 of 5 stars	$86.48 flat	$117.82 +36.2%	+433.9%	$4.73B	$2.04M	N/A	80	Positive News
NNNN Anbio Biotechnology	0.579 of 5 stars	$32.52 flat	N/A	N/A	$4.68B	$8.65M	N/A	27	News Coverage Short Interest Increase Gap Down
INDV Indivior	3.1672 of 5 stars	$37.53 flat	$39.33 +4.8%	+183.2%	$4.58B	$1.24B	19.25	1,051

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HROW) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harrow (HROW) Competitors

HROW vs. CRSP, DNTH, NNNN, INDV, and MANE

How does Harrow compare to CRISPR Therapeutics?

Summary

How does Harrow compare to Dianthus Therapeutics?

Summary

How does Harrow compare to Anbio Biotechnology?

Summary

How does Harrow compare to Indivior?

Summary

How does Harrow compare to MANE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HROW vs. The Competition

Harrow Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harrow (HROW) Competitors

HROW vs. CRSP, DNTH, NNNN, INDV, and MANE

How does Harrow compare to CRISPR Therapeutics?

Do analysts recommend CRSP or HROW?

Do institutionals and insiders hold more shares of CRSP or HROW?

Which has better valuation & earnings, CRSP or HROW?

Is CRSP or HROW more profitable?

Does the media prefer CRSP or HROW?

Which has more risk & volatility, CRSP or HROW?

Summary

How does Harrow compare to Dianthus Therapeutics?

Which has higher earnings and valuation, DNTH or HROW?

Do insiders & institutionals believe in DNTH or HROW?

Is DNTH or HROW more profitable?

Do analysts rate DNTH or HROW?

Does the media refer more to DNTH or HROW?

Which has more risk & volatility, DNTH or HROW?

Summary

How does Harrow compare to Anbio Biotechnology?

Do analysts recommend NNNN or HROW?

Which has more volatility & risk, NNNN or HROW?

Which has better valuation and earnings, NNNN or HROW?

Do insiders and institutionals hold more shares of NNNN or HROW?

Does the media favor NNNN or HROW?

Is NNNN or HROW more profitable?

Summary

How does Harrow compare to Indivior?

Do analysts rate INDV or HROW?

Which has preferable valuation & earnings, INDV or HROW?

Which has more volatility & risk, INDV or HROW?

Does the media refer more to INDV or HROW?

Is INDV or HROW more profitable?

Do insiders & institutionals have more ownership in INDV or HROW?

Summary

How does Harrow compare to MANE?

Do insiders and institutionals believe in MANE or HROW?

Which has stronger earnings & valuation, MANE or HROW?

Does the media favor MANE or HROW?

Do analysts prefer MANE or HROW?

Is MANE or HROW more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HROW vs. The Competition

Harrow Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools